CTOs on the Move

Orcabio

www.orcabio.com

 
Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients` diseased blood and immune system with a healthy one.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.orcabio.com
  • 3475 Edison Way Suite C
    Menlo Park, CA USA 94025
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Orcabio raised $192M on 06/17/2020

Similar Companies

Zyber Pharmaceuticals

Zyber Pharmaceuticals is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PDi-Pharmaceuticals

PDi-Pharmaceuticals is a Aurora, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amerigen Pharmaceuticals Inc

Amerigen Pharmaceuticals Inc is a East Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lucid Hearing

Lucid Hearing hearing aids are affordable and ensure that you hear what you need to hear when you need to hear it. Come to one of our 500+ hearing centers nationwide and receive a free hearing test today.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.